T
The New York Times
Guest
Europe’s vaccination process was expected to be well-orchestrated and efficient. So far, it’s been neither. Sabrina Tavernise, a national correspondent for The Times, spoke with our colleague Matina Stevis-Gridneff about Europe’s problems and why things could get worse before they get better.
Guest: Matina Stevis-Gridneff, the Brussels correspondent for The New York Times, covering the European Union.
Sign up here to get The Daily in your inbox each morning. And for an exclusive look at how the biggest stories on our show come together, subscribe to our newsletter.
Background reading:
For more information on today’s episode, visit nytimes.com/thedaily. Transcripts of each episode will be made available by the next workday.
Continue reading...
Guest: Matina Stevis-Gridneff, the Brussels correspondent for The New York Times, covering the European Union.
Sign up here to get The Daily in your inbox each morning. And for an exclusive look at how the biggest stories on our show come together, subscribe to our newsletter.
Background reading:
- A cascade of small decisions has led to increasingly long delays in the European Union’s inoculation efforts. While Washington went into business with the drug companies, Brussels took a conservative, budget-conscious approach that left the open market largely untouched. And it has paid for it.
- Falling behind the pace of vaccine rollouts in countries like Britain, the United States and Israel, Europe is now tightening export rules in a bid to speed up its inoculation campaign and stem political criticism.
For more information on today’s episode, visit nytimes.com/thedaily. Transcripts of each episode will be made available by the next workday.
Continue reading...